​

Molecular Partners Ownership | Who Owns Molecular Partners?


OverviewForecastChart

Molecular Partners Ownership Summary


Molecular Partners is owned by 9.26% institutional investors, and 90.74% retail investors. Suvretta capital management is the largest institutional shareholder, holding 5.94% of MOLN shares. HBM Healthcare Investments AG Ord is the top mutual fund, with 2.31% of its assets in Molecular Partners shares.

MOLN Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockMolecular Partners9.26%-90.74%
SectorHealthcare Stocks 247.07%12.15%-159.22%
IndustryBiotech Stocks 385.89%11.79%-297.68%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Suvretta capital management2.22M5.94%$8.82M
Bvf inc/il1.35M3.62%$5.36M
Morgan stanley367.000.00%$1.44K
Ubs group151.000.00%$590.00
Royal bank of canada---
Qube research---
Old mission capital---
Tang capital management---
Eversource wealth advisors---
Rhumbline advisers---

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Suvretta capital management2.22M0.23%$8.82M
Bvf inc/il1.35M0.17%$5.36M
Rhumbline advisers---
Jpmorgan chase15.00-$61.00
Ubs group151.00-$590.00
Royal bank of canada---
Qube research---
Morgan stanley367.00-$1.44K
Old mission capital---
Tang capital management---

Top Buyers

HolderShares% AssetsChange
Jpmorgan chase15.00-15.00
Bvf inc/il1.35M0.17%-
Suvretta capital management2.22M0.23%-
Morgan stanley367.00--
Qube research---16.00

Top Sellers

HolderShares% AssetsChange
Old mission capital---10.37K
Tang capital management---2.50K
Royal bank of canada---1.50K
Rhumbline advisers---269.00
Ubs group151.00--128.00

New Positions

HolderShares% AssetsChangeValue
Jpmorgan chase15.00-15.00$61.00

Sold Out

HolderChange
Qube research-16.00
Eversource wealth advisors-24.00
Rhumbline advisers-269.00
Royal bank of canada-1.50K
Tang capital management-2.50K

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 2026525.00%3,593,2870.05%910.10%2100.00%--
Mar 31, 20264-33.33%3,591,3720.08%910.43%1---100.00%
Dec 31, 20251-83.33%349-99.99%-0.00%--100.00%1-
Sep 30, 20251-83.33%155-100.00%--1-50.00%--
Jun 30, 20256-3,586,2260.10%98.78%2100.00%--100.00%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
HBM Healthcare Investments AG Ord885.74K2.31%-
Fidelity Nasdaq Composite Index795.000.00%-

MOLN Ownership FAQ


Who Owns Molecular Partners?

Molecular Partners shareholders are primarily institutional investors at 9.26%, followed by 0% insiders and 0% retail investors. The average institutional ownership in Molecular Partners's industry, Biotech Stocks , is 385.89%, which Molecular Partners falls below.

Who owns the most shares of Molecular Partners?

Molecular Partners’s largest shareholders are Suvretta capital management (2.22M shares, 5.94%), Bvf inc/il (1.35M shares, 3.62%), and Morgan stanley (367 shares, 0.00%). Together, they hold 9.56% of Molecular Partners’s total shares outstanding.

Does Blackrock own Molecular Partners?

BlackRock is not among the top 10 institutional shareholders of Molecular Partners.

Who is Molecular Partners’s biggest shareholder by percentage of total assets invested?

Suvretta capital management is Molecular Partners’s biggest shareholder by percentage of total assets invested, with 0.23% of its assets in 2.22M Molecular Partners shares, valued at 8.82M$.

Who is the top mutual fund holder of Molecular Partners shares?

HBM Healthcare Investments AG Ord is the top mutual fund holder of Molecular Partners shares, with 2.31% of its total shares outstanding invested in 885.74K Molecular Partners shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools